Cryoport, Inc.

Cryoport provides temperature-controlled supply chain solutions and cryogenic storage services for the biopharmaceutical, pharmaceutical, animal health, and reproductive medicine sectors. The company operates across two primary business segments: Life Sciences Services, which encompasses temperature-controlled logistics, cryogenic biostorage, and related support services; and Life Sciences Products, which manufactures and distributes cryogenic freezers, dewars, and shipping systems. The company's service offerings include CRYOGENE biostorage for biological materials management, IntegriCell services for cell and gene therapy logistics, and Cryoport Systems Bioservices covering storage, fulfillment, sample management, and drug product release functions.

Core product lines include the Cryoport Express and ELITE shipping systems, the HV3 cryogenic shipping platform, and the Smartpak II condition monitoring system. The company also offers cryopreservation services, specimen archiving and tracking, transportation of frozen biological materials, and consulting services for packaging qualification and custom solution development. The MVE Biological Solutions product line includes the Fusion and Vario cryogenic freezer systems acquired through prior business combinations.

Based in Brentwood, Tennessee, Cryoport employs approximately 1,090 full-time staff and operates globally across the life sciences industry. The company serves pharmaceutical manufacturers, contract research organizations, hospitals, and reproductive medicine facilities requiring specialized temperature-controlled logistics and long-term biological material storage capabilities.